A new potent beta-lactamase inhibitor, BRL 42715, with inherent activity against Bacteroides fragilis group strains.
Aldridge
K E
KE
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112-2822.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001439:Bacteroides / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D001441:Bacteroides fragilis / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D002511:Cephalosporins / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D006801:Humans; D066298:In Vitro Techniques; D007769:Lactams; D008826:Microbial Sensitivity Tests; D013045:Species Specificity; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D007769:Lactams; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; C061593:C6-(N1-methyl-1,2,3-trazolylmethylene)penem